 WARMER, Pa., March 16, 2021 GLOBE NEWSWIRE -- Arbutus Biopharma Corporation Nasdaq: ABUS, a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus HBV infection, as well as therapies to treat coronaviruses including COVID-19, today announced that it has received regulatory approval to initiate a Phase 1a1b clinical trial with AB-836, its proprietary oral capsid inhibitor for the treatment of HBV infection. 